EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
European Union seeks input from rival pharmaceutical firms on Novo Holding $16.5 billion acquisition of Catalent.
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
CIBC Asset Management Inc grew its holdings in shares of Catalent, Inc. (NYSE:CTLT – Free Report) by 7.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities ...
Baird has recently raised Catalent Inc (CTLT) stock to Outperform rating, as announced on November 16, 2023, according to Finviz. Earlier, on September 5, 2023, Argus had raised the stock from a Hold ...
Zacks.com on MSN13d
Catalent's Stock Gains Despite Q1 Earnings Miss, Gross Margin UpCTLT's solid segmental results led to an encouraging fiscal first-quarter performance, driving share prices in after-hours ...
Halozyme's strategic acquisition of Evotec and innovative ENHANZE technology present growth opportunities. Click here for a ...
The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, ...
The CEO of pharmaceuticals giant Roche said authorities should block the takeover of contract drug manufacturer Catalent by ...
Catalent (NYSE:CTLT – Get Free Report) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a report ...
Reuters on MSN14d
Catalent Misses Q1 Revenue Estimates Ahead of $16.5 Billion Deal Close With Novo HoldingsCatalent's revenue for fiscal first quarter ended Sept. 30 was $1.02 billion, marginally below analysts' estimates of $1.06 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback